Collaboration may help clinicians personalize diabetes care for patients

Eli Lilly and Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, announced a partnership to develop provider-focused tools to integrate personalized solutions for patients who use insulin for diabetes management, according to a press release from the companies.

Eli Lilly’s integrated insulin management system, currently in development, will be integrated with Rimidi’s diabetes management software platform.

“Diabetes management is a collaborative effort between people with diabetes and their health care providers,” Lucienne Ide, MD, PhD, CEO of Rimidi, said in the release. “With the right support they can achieve better results together. We are proud to partner with Lilly to facilitate personalized management of diabetes. This is a ‘better together’ story.”

Clinicians are able to personalize care for their patients by assessing individual characteristics and clinical histories using electronic medical records systems to identify individuals who may benefit from specific management approaches. The insulin management system by Eli Lilly combines a connected insulin pen with glucose-sensing technologies and software applications to deliver personalized insulin dose recommendations. The data collected from both platforms will then be delivered to physicians to “connect care.”

“To make diabetes management easier, we need to enable and empower people with diabetes to use insulin more effectively,” Marie Schiller, vice president of Eli Lilly’s Connected Care program and site head at Cambridge Innovation Center, said in the release. “Our partnership with Rimidi is one step in making this vision a reality. Diabetes is a challenge for patients and can be tough for physicians to treat. Connected care may be able to reduce many of these burdens, allowing physicians to focus on the most important clinical decisions and improving outcomes.”